You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Gefitinib

Showing 1 - 25 of 576
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor Trial in Seoul (Gefitinib)

Completed
  • Solid Tumor
  • Gefitinib
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jun 13, 2022

NSCLC, Brain Metastases, EGFR Mutation Trial in Guangzhou (Gefitinib and Pemetrexed/platinum, Gefitinib mono-therapy)

Recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Gefitinib and Pemetrexed/platinum
  • Gefitinib mono-therapy
  • Guangzhou, Guangdong, China
    Sun Yat-sen University of Cancer Center
Feb 19, 2022

Lung Cancer Trial in Boston (EGF816, Gefitinib)

Active, not recruiting
  • Lung Cancer
  • Boston, Massachusetts
    Massachusetts General Hospital
Jan 21, 2022

Ovarian Cancer, Peritoneal Tumors, Fallopian Tube Cancer Trial in Houston (Topotecan, Gefitinib)

Completed
Has Results
  • Ovarian Cancer
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 11, 2022

A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • +4 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Oct 25, 2022

    Erlotinib/Gefitinib Combined With Bevacizumab in Advanced

    Recruiting
    • Non Small Cell Lung Cancer
    • Erlotinib/Gefitinib combined with Bevacizumab
    • Changsha, Hunan, China
      Hunan Provincal Tumor Hospital
    Mar 1, 2022

    NSCLC Trial in Japan, Korea, Republic of, United States (Gefitinib, MEDI4736)

    Completed
    • Carcinoma, Non-Small-Cell Lung
    • Tampa, Florida
    • +6 more
    Mar 22, 2022

    NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +2 more
    • Nintedanib, gefitinib, erlotinib, afatinib
    • (no location specified)
    Oct 2, 2023

    Gefitinib Long-term Survivor Study

    Terminated
    • EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
      • Beijing, Beijing, China
      • +13 more
      Mar 9, 2022

      Cancer Medicines in Metastatic Non-small Cell Lung Cancer in

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • Oslo, Norway
        Pfizer Norway
      Apr 17, 2023

      NSCLC Trial in Singapore (Gefitinib)

      Completed
      • Non-small Cell Lung Cancer
      • Gefitinib
      • Singapore, Singapore
        National Cancer Centre
      May 31, 2021

      NSCLC With EGFR-Activating Mutations Trial in Worldwide (Dacomitinib (PF-00299804), Gefitinib)

      Completed
      Has Results
      • Non-small Cell Lung Cancer With EGFR-Activating Mutations
      • Dacomitinib (PF-00299804)
      • Gefitinib
      • Beijing, China
      • +51 more
      Feb 10, 2022

      Non Small Cell Lung Cancer Trial in Beijing (HS-10296, Gefitinib)

      Active, not recruiting
      • Non Small Cell Lung Cancer
      • Beijing, China
        Beijing Cancer Hospital
      Jan 19, 2022

      NSCLC Trial in Worldwide (Tepotinib, Gefitinib, Pemetrexed)

      Completed
      Has Results
      • Non-small Cell Lung Cancer
      • Beijing, China
      • +43 more
      Oct 13, 2022

      NSCLC Trial in United States (XL647)

      Completed
      • Carcinoma, Non-Small-Cell Lung
      • Gilroy, California
      • +9 more
      May 9, 2022

      EGFR-mutant NSCLC Trial in Worldwide (EGF816, trametinib, ribociclib)

      Active, not recruiting
      • EGFR-mutant Non-small Cell Lung Cancer
      • Toronto, Ontario, Canada
      • +10 more
      Dec 5, 2022

      Non-small Cell Lung Carcinoma Trial (Pembrolizumab, Paclitaxel, Carboplatin)

      Completed
      Has Results
      • Non-small Cell Lung Carcinoma
      • Pembrolizumab
      • +7 more
      • (no location specified)
      Oct 13, 2022

      Rare Tumor, Refractory Tumor Trial in Shanghai (Gefitinib, Erlotinib, Afatinib)

      Recruiting
      • Rare Tumor
      • Refractory Tumor
      • Gefitinib
      • +11 more
      • Shanghai, Shanghai, China
        Shanghai Changzheng Hospital
      Feb 16, 2022

      Hepatocellular Carcinoma, Molecular Targeted Therapy Trial in Shanghai (Lenvatinib and Gefitinib)

      Unknown status
      • Hepatocellular Carcinoma
      • Molecular Targeted Therapy
      • Lenvatinib and Gefitinib
      • Shanghai, Shanghai, China
        Renji Hospital, School of Medicine, Shanghai Jiaotong University
      Jan 13, 2021

      NSCLC Trial (Gilotrif)

      Completed
      • Non-small Cell Lung Cancer
      • (no location specified)
      Mar 18, 2021

      NSCLC Trial in Guangzhou (Apatinib Mesylate, Gefitinib)

      Recruiting
      • NSCLC
      • Apatinib Mesylate, Gefitinib
      • Guangzhou, Guangdong, China
        Sun Yat-Sen Univercity Cancer Center
      Jan 7, 2021

      Non-small-cell Lung Cancer Trial in Shanghai (gefitinib combined with chemo, gefitinib combined with apatinib, gefitinib single

      Unknown status
      • Non-small-cell Lung Cancer
      • gefitinib combined with chemotherapy
      • +2 more
      • Shanghai, Shanghai, China
        Shanghai Pulmonary Hospital;
      Jul 31, 2020

      Advanced NSCLC With EGFR Mutation Trial in Zhengzhou (S-1 plus Gefitinib, Gefitinib)

      Unknown status
      • Advanced NSCLC With EGFR Mutation
      • S-1 plus Gefitinib
      • Gefitinib
      • Zhengzhou, Henan, China
        Henan Cancer Hospital
      Jul 8, 2020

      Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma Trial in Philadelphia (drug, radiation, other)

      Completed
      • Adult Giant Cell Glioblastoma
      • +2 more
      • gefitinib
      • +2 more
      • Philadelphia, Pennsylvania
        Radiation Therapy Oncology Group
      Oct 29, 2020

      Advanced Solid Tumors Which Are cMET-dependent Trial in Worldwide (Capmatinib, Nazartinib, Gefitinib)

      Recruiting
      • Advanced Solid Tumors Which Are cMET-dependent
      • Boston, Massachusetts
      • +12 more
      Jan 27, 2023